Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia|||0000-0002-3275-8524
  • Piñero-Lambea, Carlos|||0000-0002-5263-3702
  • Segura-Morales, Carolina|||0000-0002-1746-6865
  • Tio-Gillen, Anne P.
  • Unger, Wendy W.J.
  • Burgos Castellanos, Raül|||0000-0002-4452-9235
  • Mazzolini, Rocco|||0000-0003-3249-8387
  • Miravet-Verde, Samuel
  • Jacobs, Bart C.|||0000-0002-8985-2458
  • Casas, Josefina|||0000-0002-7926-5209
  • Huizinga, Ruth
  • Lluch-Senar, Maria|||0000-0001-7568-4353
  • Serrano, Luis|||0000-0002-5276-1392
A non-pathogenic Mycoplasma pneumoniae -based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

ProTInSeq, transposon insertion tracking by ultra-deep DNA sequencing to identify translated large and small ORFs

  • Miravet-Verde, Samuel
  • Mazzolini, Rocco|||0000-0003-3249-8387
  • Segura-Morales, Carolina|||0000-0002-1746-6865
  • Broto, Alicia|||0000-0002-3275-8524
  • Lluch-Senar, Maria|||0000-0001-7568-4353
  • Serrano, Luis|||0000-0002-5276-1392
Identifying open reading frames (ORFs) being translated is not a trivial task. ProTInSeq is a technique designed to characterize proteomes by sequencing transposon insertions engineered to express a selection marker when they occur in-frame within a protein-coding gene. In the bacterium Mycoplasma pneumoniae, ProTInSeq identifies 83% of its annotated proteins, along with 5 proteins and 153 small ORF-encoded proteins (SEPs; ≤100 aa) that were not previously annotated. Moreover, ProTInSeq can be utilized for detecting translational noise, as well as for relative quantification and transmembrane topology estimation of fitness and non-essential proteins. By integrating various identification approaches, the number of initially annotated SEPs in this bacterium increases from 27 to 329, with a quarter of them predicted to possess antimicrobial potential. Herein, we describe a methodology complementary to Ribo-Seq and mass spectroscopy that can identify SEPs while providing other insights in a proteome with a flexible and cost-effective DNA ultra-deep sequencing approach.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Author Correction, ProTInSeq: transposon insertion tracking by ultra-deep DNA sequencing to identify translated large and small ORFs

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae

  • Ana, Yamile
  • Gerngross, Daniel
  • Serrano Pubull, Luis, 1982-
The non-pathogenic Mycoplasma pneumoniae engineered chassis (Mycochassis) has demonstrated the ability to express therapeutic molecules in vitro and to be effective for treatment of lung infectious diseases in in vivo mouse models. However, the expression of heterologous molecules, whether secreted or exposed on the bacterial membrane has not been optimized to ensure sufficient secretion and/or exposure levels to exert a maximum in vivo biological effect. Here, we have improved the currently used secretion signal from MPN142 protein. We found that mutations at P1' position of the signal peptide cleavage site do not abrogate secretion but affect it. Increasing hydrophobicity and mutations at the C-terminal of the signal peptide increases secretion. We tested different lipoprotein signal peptides as possible N-terminal protein anchoring motifs on the Mpn cell surface. Unexpectedly we found that these peptides exhibit variable retention and secretion rates of the protein, with some sequences behaving as full secretion motifs. This raises the question of the biological role of the lipobox motif traditionally thought to anchor membrane proteins without a helical transmembrane domain. These results altogether represent a step forward in chassis optimization, offering different sequences for secretion or membrane retention, which could be used to improve Mycochassis as a delivery vector, and broadening its therapeutic possibilities., This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreements No 670216 and 101020135). We also acknowledge the support of the Spanish Ministry of Science, Innovation and Universities through the Plan Nacional PID2021-122341NB-I00 funded by MICIU/AEI/10.13039/501100011033/FEDER, UE.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

ProTInSeq: transposon insertion tracking by ultra-deep DNA sequencing to identify translated large and small ORFs

  • Miravet Verde, Samuel, 1992-
  • Mazzolini, Rocco
  • Segura-Morales, Carolina
  • Broto, Alicia
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Identifying open reading frames (ORFs) being translated is not a trivial task. ProTInSeq is a technique designed to characterize proteomes by sequencing transposon insertions engineered to express a selection marker when they occur in-frame within a protein-coding gene. In the bacterium Mycoplasma pneumoniae, ProTInSeq identifies 83% of its annotated proteins, along with 5 proteins and 153 small ORF-encoded proteins (SEPs; ≤100 aa) that were not previously annotated. Moreover, ProTInSeq can be utilized for detecting translational noise, as well as for relative quantification and transmembrane topology estimation of fitness and non-essential proteins. By integrating various identification approaches, the number of initially annotated SEPs in this bacterium increases from 27 to 329, with a quarter of them predicted to possess antimicrobial potential. Herein, we describe a methodology complementary to Ribo-Seq and mass spectroscopy that can identify SEPs while providing other insights in a proteome with a flexible and cost-effective DNA ultra-deep sequencing approach., This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme MYCOCHASSIS (670216) and ERC LUNG-BIOREPAIR (101020135) ERC Advanced Grants (AdG). We also acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme and to the EMBL partnership. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Predicting interacting hotspots for nanobodies' binding using triplets of residues

  • Hamdani, Rahma
  • Cianferoni, Damiano
  • Reche, Raul
  • Delgado Blanco, Javier
  • Serrano Pubull, Luis, 1982-
Protein-protein interactions (PPI) are fundamental to cellular signaling, forming robust networks that govern critical biological processes such as immune response, cell growth, and signal transduction. Nanobody-based therapies have emerged as a key strategy for modulating PPIs, offering exceptional potential due to their high specificity, stability, and ability to access challenging epitopes on PPI interfaces inside cells. The rational design of nanobodies relies mainly on understanding and predicting their binding regions, particularly the residues that contribute the most to the binding energy (binding hotspots). Existing computational methods do not fully provide a scalable solution for hotspot identification in nanobody design, leaving a critical gap in the rational design of these therapeutics. Here, we present a scalable and structure-aware algorithm for hotspot prediction in nanobody design. The algorithm queries a curated database of triplets of interacting residues obtained from ~20,000 non-redundant PDB structures. We showed that these triplets contain structural and energetic information, being able to assess the stability effect of residue variations in protein structures, Pearson R = 0.63 (MSE = 1.58 kcal/mol). More important than effects on stability is the ability of the algorithm to predict binding hotspots of protein-protein generic complexes and more specifically in complexes containing nanobodies. HotspotPred reached an accuracy of 0.73 for hotspot residue identification in a protein interaction dataset of 1160 Alanine mutants and correctly identified in 63.4% of the cases we predicted at least 2 residues on the binding surface., This publication is part of the grant PRE2022-101389, funded by MICIU/AEI /10.13039/501100011033 and by the ESF+, and of the project PID2021-122341NB-I00, funded by MCIN/ AEI / 10.13039/501100011033 / FEDER, UE). This project has also received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 101020135).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Comprehensive quantitative modeling of translation efficiency in a genome-reduced bacterium

  • Weber, Marc
  • Sogues, Adrià
  • Yus, Eva
  • Burgos, Raul
  • Gallo López, Carolina, 1984-
  • Martínez, Sira
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Translation efficiency has been mainly studied by ribosome profiling, which only provides an incomplete picture of translation kinetics. Here, we integrated the absolute quantifications of tRNAs, mRNAs, RNA half-lives, proteins, and protein half-lives with ribosome densities and derived the initiation and elongation rates for 475 genes (67% of all genes), 73 with high precision, in the bacterium Mycoplasma pneumoniae (Mpn). We found that, although the initiation rate varied over 160-fold among genes, most of the known factors had little impact on translation efficiency. Local codon elongation rates could not be fully explained by the adaptation to tRNA abundances, which varied over 100-fold among tRNA isoacceptors. We provide a comprehensive quantitative view of translation efficiency, which suggests the existence of unidentified mechanisms of translational regulation in Mpn., We acknowledge the support of the CERCA Programme/Generalitat de Catalunya, the Spanish Ministry of Science and Innovation to the EMBL partnership, and the Centro de Excelencia Severo Ochoa. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 101020135 (LUNG‐BIOREPAIR) and 670216 (MYCOCHASSIS). ML‐S acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094). The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013‐2016, funded by ISCIII and ERDF. The authors would like to thank the CRG Genomics Unit for assistance with the design and sequencing of the RNA‐seq and ribosome profiling. We thank the Bukau lab (Heidelberg University) and in particular Carla Galmozzi for their help and assistance with the ribosome profiling technique. MW thanks Flomics Biotech S.L. for support during part of the research study.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia
  • Piñero-Lambea, Carlos
  • Segura-Morales, Carolina
  • Tio-Gillen, Anne P.
  • Unger, Wendy W. J.
  • Burgos, Raul
  • Mazzolini, Rocco
  • Miravet Verde, Samuel, 1992-
  • Jacobs, Bart C.
  • Casas, Josefina
  • Huizinga, Ruth
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis., This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme ERC LUNG-BIOREPAIR (101020135). We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Plan Nacional PID2021-122341NB-I00 and the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme, the Center for Industrial Technology Development (CDTI) through the Neotec programme (SNEO 20211019) and to the EMBL partnership. C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’. The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Spanish National Infrastructure for Omics Technologies (ICTS OmicsTech). We thank T. Hoogenboezem and C. Gago da Graça (Department of Pediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands) for excellent technical assistance.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia
  • Piñero-Lambea, Carlos
  • Segura-Morales, Carolina
  • Tio-Gillen, Anne P.
  • Unger, Wendy W. J.
  • Burgos, Raul
  • Mazzolini, Rocco
  • Miravet-Verde, Samuel
  • Jacobs, Bart C.
  • Casas, Josefina
  • Huizinga, Ruth
  • Lluch-Senar, Maria
  • Serrano, Luis
A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis., This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme ERC LUNG-BIOREPAIR (101020135). We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Plan Nacional PID2021-122341NB-I00 and the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme, the Center for Industrial Technology Development (CDTI) through the Neotec programme (SNEO 20211019) and to the EMBL partnership. C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’. The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Spanish National Infrastructure for Omics Technologies (ICTS OmicsTech). We thank T. Hoogenboezem and C. Gago da Graça (Department of Pediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands) for excellent technical assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Research data Set de datos (Dataset)

[Dataset] Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia
  • Piñero-Lambea, Carlos
  • Segura-Morales, Carolina
  • Tio-Gillen, Anne P.
  • Unger, Wendy W. J.
  • Burgos, Raul
  • Mazzolini, Rocco
  • Miravet-Verde, Samuel
  • Jacobs, Bart C.
  • Casas, Josefina
  • Huizinga, Ruth
  • Lluch-Senar, Maria
  • Serrano, Luis
A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis., This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme ERC LUNG-BIOREPAIR (101020135). We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Plan Nacional PID2021-122341NB-I00 and the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme, the Center for Industrial Technology Development (CDTI) through the Neotec programme (SNEO 20211019) and to the EMBL partnership. C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’. The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Spanish National Infrastructure for Omics Technologies (ICTS OmicsTech). We thank T. Hoogenboezem and C. Gago da Graça (Department of Pediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands) for excellent technical assistance., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Heterologous protein exposure and secretion optimization in Mycoplasma pneumoniae

  • Ana, Yamile
  • Gerngross, Daniel
  • Serrano Pubull, Luis, 1982-
The non-pathogenic Mycoplasma pneumoniae engineered chassis (Mycochassis) has demonstrated the ability to express therapeutic molecules in vitro and to be effective for treatment of lung infectious diseases in in vivo mouse models. However, the expression of heterologous molecules, whether secreted or exposed on the bacterial membrane has not been optimized to ensure sufficient secretion and/or exposure levels to exert a maximum in vivo biological effect. Here, we have improved the currently used secretion signal from MPN142 protein. We found that mutations at P1' position of the signal peptide cleavage site do not abrogate secretion but affect it. Increasing hydrophobicity and mutations at the C-terminal of the signal peptide increases secretion. We tested different lipoprotein signal peptides as possible N-terminal protein anchoring motifs on the Mpn cell surface. Unexpectedly we found that these peptides exhibit variable retention and secretion rates of the protein, with some sequences behaving as full secretion motifs. This raises the question of the biological role of the lipobox motif traditionally thought to anchor membrane proteins without a helical transmembrane domain. These results altogether represent a step forward in chassis optimization, offering different sequences for secretion or membrane retention, which could be used to improve Mycochassis as a delivery vector, and broadening its therapeutic possibilities., This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreements No 670216 and 101020135). We also acknowledge the support of the Spanish Ministry of Science, Innovation and Universities through the Plan Nacional PID2021-122341NB-I00 funded by MICIU/AEI/10.13039/501100011033/FEDER, UE.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ProTInSeq: transposon insertion tracking by ultra-deep DNA sequencing to identify translated large and small ORFs

  • Miravet Verde, Samuel, 1992-
  • Mazzolini, Rocco
  • Segura-Morales, Carolina
  • Broto, Alicia
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Identifying open reading frames (ORFs) being translated is not a trivial task. ProTInSeq is a technique designed to characterize proteomes by sequencing transposon insertions engineered to express a selection marker when they occur in-frame within a protein-coding gene. In the bacterium Mycoplasma pneumoniae, ProTInSeq identifies 83% of its annotated proteins, along with 5 proteins and 153 small ORF-encoded proteins (SEPs; ≤100 aa) that were not previously annotated. Moreover, ProTInSeq can be utilized for detecting translational noise, as well as for relative quantification and transmembrane topology estimation of fitness and non-essential proteins. By integrating various identification approaches, the number of initially annotated SEPs in this bacterium increases from 27 to 329, with a quarter of them predicted to possess antimicrobial potential. Herein, we describe a methodology complementary to Ribo-Seq and mass spectroscopy that can identify SEPs while providing other insights in a proteome with a flexible and cost-effective DNA ultra-deep sequencing approach., This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme MYCOCHASSIS (670216) and ERC LUNG-BIOREPAIR (101020135) ERC Advanced Grants (AdG). We also acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme and to the EMBL partnership. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comprehensive quantitative modeling of translation efficiency in a genome-reduced bacterium

  • Weber, Marc
  • Sogues, Adrià
  • Yus, Eva
  • Burgos, Raul
  • Gallo López, Carolina, 1984-
  • Martínez, Sira
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
Translation efficiency has been mainly studied by ribosome profiling, which only provides an incomplete picture of translation kinetics. Here, we integrated the absolute quantifications of tRNAs, mRNAs, RNA half-lives, proteins, and protein half-lives with ribosome densities and derived the initiation and elongation rates for 475 genes (67% of all genes), 73 with high precision, in the bacterium Mycoplasma pneumoniae (Mpn). We found that, although the initiation rate varied over 160-fold among genes, most of the known factors had little impact on translation efficiency. Local codon elongation rates could not be fully explained by the adaptation to tRNA abundances, which varied over 100-fold among tRNA isoacceptors. We provide a comprehensive quantitative view of translation efficiency, which suggests the existence of unidentified mechanisms of translational regulation in Mpn., We acknowledge the support of the CERCA Programme/Generalitat de Catalunya, the Spanish Ministry of Science and Innovation to the EMBL partnership, and the Centro de Excelencia Severo Ochoa. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 101020135 (LUNG‐BIOREPAIR) and 670216 (MYCOCHASSIS). ML‐S acknowledges the support from FEDER project from Instituto Carlos III (ISCIII, Acción Estratégica en Salud 2016) (reference CP16/00094). The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013‐2016, funded by ISCIII and ERDF. The authors would like to thank the CRG Genomics Unit for assistance with the design and sequencing of the RNA‐seq and ribosome profiling. We thank the Bukau lab (Heidelberg University) and in particular Carla Galmozzi for their help and assistance with the ribosome profiling technique. MW thanks Flomics Biotech S.L. for support during part of the research study.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Predicting interacting hotspots for nanobodies' binding using triplets of residues

  • Hamdani, Rahma
  • Cianferoni, Damiano
  • Reche, Raul
  • Delgado Blanco, Javier
  • Serrano Pubull, Luis, 1982-
Protein-protein interactions (PPI) are fundamental to cellular signaling, forming robust networks that govern critical biological processes such as immune response, cell growth, and signal transduction. Nanobody-based therapies have emerged as a key strategy for modulating PPIs, offering exceptional potential due to their high specificity, stability, and ability to access challenging epitopes on PPI interfaces inside cells. The rational design of nanobodies relies mainly on understanding and predicting their binding regions, particularly the residues that contribute the most to the binding energy (binding hotspots). Existing computational methods do not fully provide a scalable solution for hotspot identification in nanobody design, leaving a critical gap in the rational design of these therapeutics. Here, we present a scalable and structure-aware algorithm for hotspot prediction in nanobody design. The algorithm queries a curated database of triplets of interacting residues obtained from ~20,000 non-redundant PDB structures. We showed that these triplets contain structural and energetic information, being able to assess the stability effect of residue variations in protein structures, Pearson R = 0.63 (MSE = 1.58 kcal/mol). More important than effects on stability is the ability of the algorithm to predict binding hotspots of protein-protein generic complexes and more specifically in complexes containing nanobodies. HotspotPred reached an accuracy of 0.73 for hotspot residue identification in a protein interaction dataset of 1160 Alanine mutants and correctly identified in 63.4% of the cases we predicted at least 2 residues on the binding surface., This publication is part of the grant PRE2022-101389, funded by MICIU/AEI /10.13039/501100011033 and by the ESF+, and of the project PID2021-122341NB-I00, funded by MCIN/ AEI / 10.13039/501100011033 / FEDER, UE). This project has also received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 101020135).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia
  • Piñero-Lambea, Carlos
  • Segura-Morales, Carolina
  • Tio-Gillen, Anne P.
  • Unger, Wendy W. J.
  • Burgos, Raul
  • Mazzolini, Rocco
  • Miravet Verde, Samuel, 1992-
  • Jacobs, Bart C.
  • Casas, Josefina
  • Huizinga, Ruth
  • Lluch-Senar, Maria 1982-
  • Serrano Pubull, Luis, 1982-
A non-pathogenic Mycoplasma pneumoniae-based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis., This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme ERC LUNG-BIOREPAIR (101020135). We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Plan Nacional PID2021-122341NB-I00 and the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), the Generalitat de Catalunya through the CERCA programme, the Center for Industrial Technology Development (CDTI) through the Neotec programme (SNEO 20211019) and to the EMBL partnership. C.P.-L. acknowledges the support of ‘Programa Torres Quevedo’ grant [PTQ2020-011048] funded by MCIN/AEI/10.13039/501100011033; European Union ‘NextGenerationEU/PRTR’. The proteomics analyses were performed in the CRG/UPF Proteomics Unit which is part of the Spanish National Infrastructure for Omics Technologies (ICTS OmicsTech). We thank T. Hoogenboezem and C. Gago da Graça (Department of Pediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands) for excellent technical assistance.